Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E, Demolis P, Moreau A, Hemmings RJ, O'Connor D, Brown D, Shepard T, Abadie E, Pignatti F. Pean E, et al. Oncologist. 2012;17(4):543-9. doi: 10.1634/theoncologist.2011-0364. Epub 2012 Apr 3. Oncologist. 2012. PMID: 22477727 Free PMC article. Review.
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F. Pean E, et al. Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24. Clin Cancer Res. 2012. PMID: 22829199
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.
Péan E, Flores B, Hudson I, Sjöberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. Péan E, et al. Oncologist. 2013;18(5):625-33. doi: 10.1634/theoncologist.2013-0020. Epub 2013 Apr 24. Oncologist. 2013. PMID: 23615696 Free PMC article.
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
Delgado J, Pean E, Melchiorri D, Migali C, Josephson F, Enzmann H, Pignatti F. Delgado J, et al. Among authors: pean e. ESMO Open. 2021 Apr;6(2):100087. doi: 10.1016/j.esmoop.2021.100087. Epub 2021 Mar 16. ESMO Open. 2021. PMID: 33735800 Free PMC article. Review.
The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.
Araujo-Fernandez I, Delgado J, Moscetti L, Sarac SB, Zander H, Mueller-Egert S, Dunder K, Pean E, Bergmann L, Enzmann H, Pignatti F. Araujo-Fernandez I, et al. Among authors: pean e. ESMO Open. 2021 Feb;6(1):100008. doi: 10.1016/j.esmoop.2020.100008. Epub 2020 Dec 16. ESMO Open. 2021. PMID: 33399074 Free PMC article. Review.
European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma.
Ali S, Camarero J, Hennik P, Bolstad B, Sommerfelt Grønvold M, Syvertsen C, Oddvar Strøm B, Ökvist M, Josephson F, Keller-Stanislawski B, Zafiropoulos N, Pean E, Bergh J, da Rocha Dias S, Pignatti F. Ali S, et al. Among authors: pean e. ESMO Open. 2020 Nov;5(6):e000798. doi: 10.1136/esmoopen-2020-000798. ESMO Open. 2020. PMID: 33188050 Free PMC article. Review.
Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements.
Eichler HG, Adams R, Andreassen E, Arlett P, van de Casteele M, Chapman SJ, Goettsch WG, Martinsson JL, Llinares-Garcia J, Nachtnebel A, Pean E, Rasi G, Reksten TR, Timmers L, Vreman RA, van de Vijver I, Wenzl M. Eichler HG, et al. Among authors: pean e. Int J Technol Assess Health Care. 2021 Aug 23;37(1):e83. doi: 10.1017/S026646232100057X. Int J Technol Assess Health Care. 2021. PMID: 34424152
Histology independent drug development - Is this the future for cancer drugs?
Billingham L, Brown L, Framke T, Greystoke A, Hovig E, Mathur S, Page P, Pean E, Barjesteh van Waalwijk van Doorn-Khosrovani S, Vonk R, Wissink S, Zander H, Plummer R. Billingham L, et al. Among authors: pean e. Cancer Treat Rev. 2024 Feb;123:102674. doi: 10.1016/j.ctrv.2023.102674. Epub 2023 Dec 23. Cancer Treat Rev. 2024. PMID: 38176220 Free article. Review.
14 results